DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Information source: Duke University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Immunosuppression

Intervention: Belatacept (Drug); Hand transplant (Procedure)

Phase: Phase 2

Status: Recruiting

Sponsored by: Linda Cendales, MD

Official(s) and/or principal investigator(s):
Linda Cendales, MD, Principal Investigator, Affiliation: Duke University

Overall contact:
Linda Cendales, MD, Phone: 919-681-7514, Email: linda.cendales@duke.edu

Summary

The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test. Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation. Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).

Clinical Details

Official title: Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.

Secondary outcome:

Clinical rejection

Histological rejection

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Patients from 18-65 years old with loss of limb 2. Willingness and legal ability to give informed consent 3. Willingness to travel to study site for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail Exclusion Criteria:

- Any condition that precludes serial follow-up

- Any condition that would likely increase the risk of protocol participation or

confound the interpretation of the data

- Any active malignancy or any history of a malignancy or lymphoma

- Inability or unwillingness to comply with protocol monitoring and therapy and

immunodeficiency syndrome(s)

Locations and Contacts

Linda Cendales, MD, Phone: 919-681-7514, Email: linda.cendales@duke.edu

Duke University Medical Center, Durham, North Carolina 27710, United States; Recruiting
Additional Information

Starting date: March 2015
Last updated: March 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017